BIOCRYST PHARMACEUTICA

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jul 2023 07:00:12 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jun 2023 07:00:42 By Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conference

01 Jun 2023 07:00:45 By Nasdaq GlobeNewswire

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress

31 May 2023 07:02:04 By Nasdaq GlobeNewswire

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile

22 May 2023 07:00:00 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 May 2023 16:01:01 By Nasdaq GlobeNewswire

BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update

03 May 2023 07:00:55 By Nasdaq GlobeNewswire

BioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat)

27 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

BioCryst to Report First Quarter 2023 Financial Results on May 3

19 Apr 2023 07:00:27 By Nasdaq GlobeNewswire

BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon

18 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

12 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Apr 2023 07:00:36 By Nasdaq GlobeNewswire

BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

31 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

BioCryst Celebrates Bob Ingram’s Contributions to the Company’s Success

29 Mar 2023 16:01:31 By Nasdaq GlobeNewswire

CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada

08 Mar 2023 15:00:00 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Mar 2023 07:00:13 By Nasdaq GlobeNewswire

BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)

24 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

22 Feb 2023 07:00:04 By Nasdaq GlobeNewswire

BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones

21 Feb 2023 07:00:23 By Nasdaq GlobeNewswire

BioCryst to Report Fourth Quarter 2022 Financial Results on February 21

07 Feb 2023 07:00:16 By Nasdaq GlobeNewswire